FDA Regulations for PACA and Medical Imaging Software : A Complete 2026 Guide

 FDA Regulations for PACA and Medical Imaging Software : A Complete 2026 Guide

You can spend months building medical imaging software, only to discover a costly surprise. One wrong FDA classification can delay your launch or keep your product off the US market. 

That’s the reality for many healthcare software companies. Whether you’re developing a DICOM viewer, PACS platform, or AI-powered imaging solution, understanding the FDA regulations for medical imaging software is essential from the start.

What Counts as Medical Imaging Software Under FDA Rules?

Not all medical imaging software is regulated by the FDA. What matters isn’t whether your software works with medical images, but what it’s designed to do.

If your software analyzes, processes, or helps diagnose a medical condition, it’s likely regulated as a medical device. If it simply stores, displays, or transfers images without influencing clinical decisions, it may not fall under FDA regulation.

Understanding this distinction is the first step toward choosing the right regulatory pathway.

1. Software as a Medical Device (SaMD) vs. Embedded Software

Software is considered Software as a Medical Device (SaMD) when it performs a medical function on its own. It does this without being part of a physical medical device. The FDA follows the definition established by the IMDRF.

For example, AI software that detects tumors from CT scans is SaMD because it performs a diagnostic function independently.

In contrast, software built into a CT scanner or MRI machine is embedded software. Since it operates as part of the hardware, it is regulated along with the medical device itself.

2. The Intended Use Test

The FDA regulates software based on its intended use, not just its technical capabilities.

For example, a DICOM viewer marketed to help radiologists detect diseases is making a diagnostic claim and is likely regulated. However, if the same viewer is intended only for education, research, or image reference, it may not require FDA clearance.

This is why your product claims, documentation, and marketing are just as important as the software itself.

3. Which Software Is Not Regulated?

Not every healthcare application is considered a medical device.

General wellness apps, such as fitness trackers, step counters, or sleep monitoring apps, usually fall outside FDA regulation. They do not diagnose or treat medical conditions.

However, once software analyzes medical images or provides information that clinicians use for diagnosis or treatment, it typically becomes subject to FDA regulations. Understanding where your product falls is one of the most important decisions you’ll make before development begins.

The PACS to MIMPS Shift: What Changed and Why

One of the biggest changes in FDA regulations for medical imaging software is the transition from Picture Archiving and Communication Systems (PACS) to Medical Image Management and Processing Systems (MIMPS). Understanding this change is essential because it determines which software functions require FDA regulation.

The change came after the 21st Century Cures Act, which removed certain low-risk software functions from the FDA’s definition of a medical device. To reflect these updates, the FDA replaced the traditional PACS regulation with MIMPS.

Under the current rules, software that only stores, displays, transfers, or converts medical images is generally not regulated as a medical device.

However, software that processes, analyzes, or enhances medical images is still regulated. This includes features such as:

Image enhancement

Image segmentation

Quantitative measurements

Multi-modality image registration

3D visualization

AI-powered image analysis

In simple terms, moving or viewing medical images is generally exempt, but software that helps clinicians interpret those images remains subject to FDA regulations. This distinction is critical when planning your product’s features and regulatory pathway.

Also Read: What Is The Difference Between DICOM and PACS?

FDA Device Classification for Medical Imaging Software

If your medical imaging software is considered a medical device, the next step is determining its FDA risk class. The FDA divides medical devices into three classes based on the level of risk. Your device class determines the regulatory requirements and approval pathway.

1. Class I: Low Risk

Class I includes low-risk devices. Most are exempt from FDA premarket review, although they must still meet basic requirements such as registration, labeling, and quality controls.

Some basic medical image management tools may fall into this category.

2. Class II: Moderate Risk

Most medical imaging software falls under Class II, including many MIMPS solutions and AI-powered imaging applications.

These devices typically require 510(k) clearance before they can be marketed and must comply with both general and special FDA controls.

3. Class III: High Risk

Class III includes high-risk software that supports critical clinical decisions or could seriously impact patient safety if it fails.

These devices require Premarket Approval (PMA), the FDA’s most rigorous review process, which usually includes clinical evidence.

Note: FDA device classes are different from IMDRF risk categories. The FDA classifies devices based on regulatory risk. The IMDRF instead evaluates software by the severity of the condition and how much it influences clinical decisions. 

AI and Machine Learning in Medical Imaging: Special FDA Requirements

AI is transforming medical imaging, but it also comes with additional FDA requirements. Unlike traditional software, AI models can learn, improve, and change over time, which creates new regulatory challenges.

1. Locked vs. Adaptive AI Models

A locked AI model always produces the same result for the same input and is easier for the FDA to evaluate. 

An adaptive AI model can change as it learns from new data. Because its behavior evolves over time, it requires additional oversight and monitoring.

2. Predetermined Change Control Plan (PCCP)

The FDA allows developers to plan certain AI model updates in advance through a Predetermined Change Control Plan (PCCP).

With an approved PCCP, eligible updates can be implemented without submitting a new FDA application each time, provided they follow the approved plan.

3. Use High-Quality Training Data

The FDA expects AI models to be trained and validated using representative, high-quality datasets. You should also document model performance across different patient groups and clearly identify any known limitations or potential bias.

4. Monitor AI After Launch

FDA compliance doesn’t end after clearance. AI models should be continuously monitored to ensure they remain accurate and safe as new data, imaging devices, and clinical environments evolve.

A strong post-market monitoring plan helps maintain compliance while ensuring consistent real-world performance.

Read full Article : FDA Regulations for PACS and Medical Imaging Software: A Complete 2026 Guide